The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback